Ameritas Investment Partners, Inc. - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$52,496
+9.4%
6,083
+31.2%
0.00%0.0%
Q2 2023$47,993
-4.6%
4,6370.0%0.00%0.0%
Q1 2023$50,311
-0.5%
4,6370.0%0.00%0.0%
Q4 2022$50,543
+7.5%
4,6370.0%0.00%0.0%
Q3 2022$47,000
+11.9%
4,6370.0%0.00%0.0%
Q2 2022$42,000
-4.5%
4,6370.0%0.00%0.0%
Q1 2022$44,000
-13.7%
4,6370.0%0.00%0.0%
Q4 2021$51,000
+82.1%
4,637
+22.2%
0.00%
+100.0%
Q3 2021$28,000
-49.1%
3,7940.0%0.00%
-50.0%
Q2 2021$55,000
-28.6%
3,7940.0%0.00%
-33.3%
Q1 2021$77,000
+1.3%
3,794
-11.4%
0.00%0.0%
Q4 2020$76,000
+20.6%
4,2820.0%0.00%0.0%
Q3 2020$63,000
-30.0%
4,2820.0%0.00%
-25.0%
Q2 2020$90,000
-2.2%
4,282
+7.8%
0.00%
-20.0%
Q1 2020$92,000
-3.2%
3,972
+8.3%
0.01%
+25.0%
Q4 2019$95,000
+33.8%
3,6660.0%0.00%
+33.3%
Q3 2019$71,000
+18.3%
3,6660.0%0.00%0.0%
Q2 2019$60,000
-27.7%
3,6660.0%0.00%
-25.0%
Q1 2019$83,000
-11.7%
3,6660.0%0.00%
-20.0%
Q4 2018$94,000
-21.7%
3,6660.0%0.01%
-16.7%
Q3 2018$120,000
+44.6%
3,6660.0%0.01%
+50.0%
Q2 2018$83,000
-6.7%
3,6660.0%0.00%0.0%
Q1 2018$89,000
-40.7%
3,666
-5.1%
0.00%
-42.9%
Q4 2017$150,000
+20.0%
3,8650.0%0.01%
+16.7%
Q3 2017$125,000
-18.3%
3,8650.0%0.01%
-14.3%
Q2 2017$153,000
+15.0%
3,865
+6.3%
0.01%0.0%
Q1 2017$133,000
+1800.0%
3,635
+1494.3%
0.01%
Q4 2016$7,000
-12.5%
2280.0%0.00%
Q3 2016$8,000
+60.0%
2280.0%0.00%
Q2 2016$5,000
+25.0%
2280.0%0.00%
Q1 2016$4,000
+33.3%
2280.0%0.00%
Q4 2015$3,0002280.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders